A Study of Elenestinib in Healthy Adult Female Participants
Phase 1
18–65
Female only
1 site in AZ
What this study is about
This Phase 1 study is testing Elenestinib in people with healthy volunteers. The primary outcome being measured is Apparent first-order terminal elimination half-life (t1/2).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
kinase inhibitor, ethinylestradiol, progestin (hormonal contraceptive), midazolam (Benzodiazepine; short-acting)
oral (Oral Tablet), injection
Primary: Apparent first-order terminal elimination half-life (t1/2), Apparent total plasma clearance after oral administration (CL/F), Maximum observed concentration (Cmax), Percent of AUC0-inf extrapolated (AUC%extrap), Time to reach Cmax (Tmax)
Secondary: Number of participants with treatment-emergent adverse events (TEAEs)